Mineralys Therapeutics, Inc.
MLYS Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$20.55
KIRA · Stoqly’s AI analyst, in plain words
- Mineralys Therapeutics, Inc. lost $155M in fiscal 2025.
- Free cash flow was −$142M in fiscal 2025, — of revenue.
Market cap
$1.7B
P/E
—
Revenue
—
Net income
−$155M
Free cash flow
−$142M
Operating margin
—
Mineralys Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$155M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Mineralys Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- Mineralys Therapeutics, Inc.
- CIK
- 0001933414
Mineralys Therapeutics, Inc. · MLYS
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Net income | −$29.8M | −$71.9M | −$178M | −$155M |
| Diluted EPS | −$5.77 | −$1.99 | −$3.66 | −$2.29 |
| Cash | ||||
| Cash from operations | −$29.2M | −$81.2M | −$166M | −$142M |
| Capital expenditure | — | $0.0M | $0.1M | $0.0M |
| Free cash flow | — | −$81.2M | −$166M | −$142M |
| Share count change | — | 600.3% | 34.1% | 39.4% |
| Debt and strength | ||||
| Cash and short-term investments | $87.7M | $49.3M | $114M | $173M |
| Shareholders' equity | −$52.3M | $241M | $191M | $647M |
| Current ratio | 14.0x | 23.8x | 14.0x | 43.8x |
| Returns and quality | ||||
| Return on equity | — | −76.1% | −82.2% | −36.9% |
| Return on tangible equity | — | −29.8% | −93.0% | −23.9% |
| Altman Z'' | 2.3 | 26.5 | 8.7 | 47.4 |
Insiders bought, 12 months
$8.8M
1 insider
Insiders sold, 12 months
$88.0M
8 insiders
Of sales under plans
28%
$24.9M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Mineralys Therapeutics, Inc. · MLYS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $20.55 a share, the company is worth $1.7B.
Source: SEC EDGAR XBRL filings (CIK 0001933414). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.